{"id":"intradetrusor-botox-injections","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Urinary tract infection"},{"rate":"5-15","effect":"Urinary retention"},{"rate":"5-10","effect":"Hematuria"},{"rate":"5-10","effect":"Dysuria"},{"rate":"5-15","effect":"Incomplete bladder emptying"}]},"_chembl":{"chemblId":"CHEMBL1795072","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Botulinum toxin type A cleaves SNARE proteins required for acetylcholine vesicle release, thereby inhibiting parasympathetic signaling to the detrusor muscle. This reduces the frequency and intensity of involuntary bladder contractions, increasing bladder capacity and reducing urinary urgency and incontinence episodes.","oneSentence":"Botulinum toxin injected into the detrusor muscle blocks acetylcholine release at the neuromuscular junction, reducing involuntary bladder contractions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:30.792Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with urge incontinence"},{"name":"Neurogenic detrusor overactivity in spinal cord injury patients"}]},"trialDetails":[{"nctId":"NCT05308979","phase":"PHASE4","title":"Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2022-05-01","conditions":"Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome","enrollment":116},{"nctId":"NCT06438861","phase":"NA","title":"Role of Combination Therapy in Women With Refractory Overactive Bladder","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-01-01","conditions":"Overactive Bladder Syndrome","enrollment":""},{"nctId":"NCT07387315","phase":"PHASE4","title":"A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections","status":"NOT_YET_RECRUITING","sponsor":"TriHealth Inc.","startDate":"2026-02","conditions":"Overactive Bladder, Neurogenic Bladder, Urge Incontinence","enrollment":96},{"nctId":"NCT02816151","phase":"PHASE3","title":"Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2011-02","conditions":"Neurogenic Vesical Hyperactivity Syndrom","enrollment":29},{"nctId":"NCT05806164","phase":"PHASE4","title":"Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence","status":"RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2023-06-06","conditions":"Urgency Urinary Incontinence","enrollment":432},{"nctId":"NCT07025044","phase":"","title":"Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections","status":"RECRUITING","sponsor":"Alexis Dieter","startDate":"2025-09-03","conditions":"Overactive Bladder (OAB), Urge Incontinence","enrollment":40},{"nctId":"NCT06514430","phase":"PHASE4","title":"Prophylactic Analgesia for Bladder Botox Injections","status":"WITHDRAWN","sponsor":"Montefiore Medical Center","startDate":"2025-07","conditions":"Urinary Incontinence, Urinary Incontinence, Urge, Overactive Bladder","enrollment":""},{"nctId":"NCT05968885","phase":"PHASE4","title":"Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2021-10-01","conditions":"Urinary Bladder, Overactive, Urodynamics, Effect of Drug","enrollment":300},{"nctId":"NCT06953271","phase":"PHASE4","title":"Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection","status":"NOT_YET_RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2025-05-15","conditions":"Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis)","enrollment":164},{"nctId":"NCT05652036","phase":"PHASE4","title":"Procedural Discomfort Related to Number of Intradetrusor Botox Injections","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2022-07-07","conditions":"Overactive Bladder","enrollment":108},{"nctId":"NCT06387329","phase":"PHASE4","title":"Bladder Botox UTI Antibiotic Prophylaxis","status":"RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2024-04-04","conditions":"Overactive Bladder, Bladder Pain Syndrome","enrollment":100},{"nctId":"NCT06729151","phase":"","title":"Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome","status":"RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2024-11-01","conditions":"Bladder Pain Syndrome, Female Sexual Dysfunction","enrollment":159},{"nctId":"NCT06569342","phase":"","title":"Botulinum Neurotoxin Type A (BoNT-A) in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2022-01-15","conditions":"Overactive Bladder, Incontinence, Daytime Urinary, Incontinence, Nighttime Urinary","enrollment":43},{"nctId":"NCT06483217","phase":"NA","title":"Optimal Injection Interval for Intra-Detrusor Botulinum Toxin","status":"NOT_YET_RECRUITING","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2024-07","conditions":"Overactive Bladder, Urinary Urgency, Urinary Incontinence","enrollment":100},{"nctId":"NCT06437899","phase":"NA","title":"Evaluation of Efficacy and Patient Satisfaction of Local Anaesthesia Versus Sedoanalgesia for Botox (R) Injection in the Urinary Bladder for the Treatment of Idiopathic Overactive Bladder","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital LKH Hochsteiermark - Leoben","startDate":"2023-09-01","conditions":"Overactive Bladder","enrollment":84},{"nctId":"NCT04124939","phase":"PHASE4","title":"Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-11-10","conditions":"Overactive Bladder","enrollment":41},{"nctId":"NCT04479709","phase":"","title":"The Urinary Microbiome in Patients Receiving Intradetrusor Botox Injections","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2021-01-01","conditions":"Overactive Bladder","enrollment":60},{"nctId":"NCT06250543","phase":"PHASE4","title":"Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder","status":"COMPLETED","sponsor":"Niko Kavcic","startDate":"2018-08-14","conditions":"Overactive Bladder","enrollment":64},{"nctId":"NCT04401176","phase":"PHASE2","title":"Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome","status":"COMPLETED","sponsor":"Walter Reed National Military Medical Center","startDate":"2020-09-15","conditions":"Interstitial Cystitis, Bladder Pain Syndrome","enrollment":58},{"nctId":"NCT05911594","phase":"NA","title":"IDB Injection Combined With PTNS for Managing Children With OAB Not Responding to Monotherapy","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-02-14","conditions":"BOTOX, Percutaneous Tibial Nerve Stimulation","enrollment":128},{"nctId":"NCT02097121","phase":"PHASE3","title":"OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)","status":"TERMINATED","sponsor":"Allergan","startDate":"2014-05-23","conditions":"Urinary Incontinence, Urinary Bladder, Overactive","enrollment":56},{"nctId":"NCT02660359","phase":"PHASE3","title":"Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2","status":"TERMINATED","sponsor":"Ipsen","startDate":"2016-07-08","conditions":"Urinary Incontinence, Overactive Bladder","enrollment":258},{"nctId":"NCT02660138","phase":"PHASE3","title":"Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1","status":"TERMINATED","sponsor":"Ipsen","startDate":"2016-03","conditions":"Urinary Incontinence, Overactive Bladder","enrollment":227},{"nctId":"NCT03758235","phase":"PHASE3","title":"Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin","status":"UNKNOWN","sponsor":"University Of Perugia","startDate":"2018-09-01","conditions":"Overactive Bladder Syndrome","enrollment":140},{"nctId":"NCT04305743","phase":"PHASE4","title":"Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A","status":"RECRUITING","sponsor":"University of South Florida","startDate":"2019-10-09","conditions":"Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary","enrollment":60},{"nctId":"NCT04578782","phase":"PHASE2","title":"Efficacy of OnabotulinumtoxinA in Migraine","status":"COMPLETED","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2018-03-13","conditions":"Migraine","enrollment":32},{"nctId":"NCT04020510","phase":"PHASE4","title":"Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder","status":"RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2019-07-01","conditions":"Overactive Bladder","enrollment":184},{"nctId":"NCT02298660","phase":"PHASE4","title":"Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI","status":"COMPLETED","sponsor":"Rick Hansen Institute","startDate":"2013-04","conditions":"Autonomic Dysreflexia","enrollment":55},{"nctId":"NCT00578097","phase":"PHASE2","title":"Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder","status":"TERMINATED","sponsor":"Ipsen","startDate":"2008-02","conditions":"Overactive Bladder","enrollment":81},{"nctId":"NCT04075578","phase":"","title":"Evaluation of Professional Practices in the Treatment of Refractory Idiopathic Overactive Bladder at the Dose of 50 Units (TOX50IUU)","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2019-06-26","conditions":"Bladder, Overactive","enrollment":60},{"nctId":"NCT01767519","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-03-01","conditions":"Overactive Bladder, Urinary Incontinence","enrollment":356},{"nctId":"NCT01768910","phase":"NA","title":"Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2011-12","conditions":"Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, Overactive Bladder","enrollment":91},{"nctId":"NCT02995967","phase":"NA","title":"Evaluation of Botulinum Toxin A Alone Versus Botulinum Toxin A With Hydrodistension for Treatment of Overactive Bladder","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2016-11","conditions":"Overactive Bladder","enrollment":3},{"nctId":"NCT01220726","phase":"PHASE3","title":"Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2009-06","conditions":"Overactive Bladder","enrollment":30},{"nctId":"NCT02078895","phase":"PHASE3","title":"Randomization of Botox for Stent Pain and Irritative Voiding Symptoms","status":"TERMINATED","sponsor":"University of California, Irvine","startDate":"2014-02","conditions":"Lower Urinary Tract Discomfort, Stent Pain","enrollment":15},{"nctId":"NCT01166438","phase":"PHASE3","title":"Anticholinergic vs. Botox Comparison Study","status":"COMPLETED","sponsor":"NICHD Pelvic Floor Disorders Network","startDate":"2010-03","conditions":"Urge Urinary Incontinence, Overactive Bladder","enrollment":249},{"nctId":"NCT03407183","phase":"","title":"The Efficacy of Botulinum Toxin in Spastic Neuropathic Bladder","status":"UNKNOWN","sponsor":"AHMED FARAHAT HASSAN","startDate":"2018-01-01","conditions":"Spastic Neurogenic Bladder","enrollment":20},{"nctId":"NCT01226706","phase":"NA","title":"Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence","status":"COMPLETED","sponsor":"Saskatchewan Health Authority - Regina Area","startDate":"2008-06","conditions":"Urinary Urge Incontinence","enrollment":21},{"nctId":"NCT01337024","phase":"","title":"Heart Rate Variability (HRV) in Patients With Neurogenic Detrusor Overactivity (NDO) Before and After Botulinum Neurotoxin Type A (BoNT/A) Intradetrusor Injections","status":"COMPLETED","sponsor":"Balgrist University Hospital","startDate":"2010-03","conditions":"Bladder Disorder, Neurogenic","enrollment":36},{"nctId":"NCT02009540","phase":"PHASE4","title":"Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity","status":"UNKNOWN","sponsor":"Mr HD Flood","startDate":"2013-12","conditions":"Overactive Detrusor","enrollment":60},{"nctId":"NCT01477736","phase":"NA","title":"A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"Centro de Reabilitação e Readaptação Dr. Henrique Santillo","startDate":"2009-01","conditions":"Spinal Cord Injury","enrollment":68},{"nctId":"NCT00479596","phase":"PHASE2, PHASE3","title":"This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.","status":"UNKNOWN","sponsor":"Urological Sciences Research Foundation","startDate":"2007-01","conditions":"Overactive Bladder","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Intradetrusor Botox Injections","genericName":"Intradetrusor Botox Injections","companyName":"The Methodist Hospital Research Institute","companyId":"the-methodist-hospital-research-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"Botulinum toxin injected into the detrusor muscle blocks acetylcholine release at the neuromuscular junction, reducing involuntary bladder contractions. Used for Overactive bladder with urge incontinence, Neurogenic detrusor overactivity in spinal cord injury patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}